The preclinical evaluation of drug-induced cardiotoxicity is an important stage in the drug development process; however, traditional methods for screening drug candidates, such as cardiomyocyte-based ...

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...

Learn how drug absorption and predictive modeling drive advancements in pharmaceuticals and precision medicine.

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

Nowadays, in silico methodologies have become a crucial part of the drug discovery process. This is mostly because they can impact the entire drug development trajectory, identifying and discovering ...

Jean-Pierre Latere, CEO, EsoBiotec, said: “We look forward to working with AstraZeneca, a global leader in drug development, to advance our shared goal of bringing transformative cost-effective cell ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell ...

Google is expanding its health-related AI summaries in search to enhance its impact in the health sector. Powered by the ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapyMONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a ...

but what we have done is engineered it specifically for use in vivo,” Phil Johnson, CEO of Interius BioTherapeutics, said. “That took us a while. That was a couple of years’ long process to ...

British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of ...